Alnylam's Biotherapeutics Unit Could Strike Industry Deals in 'Near Term' | GenomeWeb

By Doug Macron

Alnylam Pharmaceuticals expects its biologics unit may soon secure industry deals centering around either drugs in development or ones already on the market, company officials said last week.

"We've really been very encouraged by the robust response to the [establishment] of this initiative," Stuart Pollard, Alnylam's vice president of scientific and business strategy, said during a conference call held last week to discuss the company's first-quarter financial results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.